Genomic study of rare children's cancer yields possible prognostic tool

August 9, 2012 in Cancer

A new study of the genetic makeup, or genome, of Ewing sarcoma, a rare cancer that strikes children, teenagers, and young adults, has produced multiple discoveries: a previously unknown sarcoma subtype, genetic factors related to long-term survival, and identification of a genetic change between the primary and metastatic stages of the disease that could lead to better, more targeted treatment.

Researchers from Huntsman Institute (HCI) at the University of Utah used a new, advanced technology called molecular inversion probes (MIPs) to analyze in the genome of Ewing tumors. The report appears today in the online issue of the journal .

New Subtype of Ewing Sarcoma

According to the study's principal investigator, Joshua Schiffman, M.D., associate professor of pediatrics at the University of Utah and an HCI investigator, up to 10 percent of the tumor samples revealed that DNA in a specific region of the genome was missing, including a gene called SMARCB1. The same deletion had been described before in another aggressive and deadly sarcoma called a rhabdoid tumor. Pathologists double-checked the diagnosis on these samples and determined that they were not misdiagnosed rhabdoid tumors, but were indeed Ewing sarcoma that also had this rhabdoid characteristic.

"Discovering this new subset of Ewing sarcoma is especially important because the patients with this deletion were among the long-term survivors," said Schiffman. "It opens up questions about the biology of this tumor and whether patients with this type of cancer need different treatment."

Genome Factors Correlate with Long-Term Survival

The researchers also looked at the relationship between the Ewing sarcoma genome and and found factors in eight areas of the genome correlated in varying degrees with long-term survival after diagnosis. They compared the samples that contained none of these factors to those with one or more. Outcomes for the patients with none of the factors were considerably better: 80 percent of them had no recurrence of the disease after initial treatment, and even more outstanding, 100 percent survived more than 12 years after diagnosis. For patients with one or more of the factors, only about 40 percent survived that long.

"Our results will have to be validated with a larger number of samples, but MIPs give us the tool to do that on clinically archived samples," said Schiffman. "Clearly, learning more about cancers with these genomic factors will be essential to finding new treatments that will improve overall survival among all Ewing sarcoma patients."

Gene Difference in Metastatic Ewing Sarcoma Cells

The current model for how cancer spreads, or metastasizes, in the body holds that primary tumors change in some way that allows the cancer cells to spin off and move to other parts of the body. The researchers compared the DNA differences between primary tumor (the initial location of the cancer) cells, metastasized cells, and normal cells in the same patients.

"We found a specific gene that was present only in the metastatic tumors and not the primary tumor or normal cells," said Schiffman. "That gene has been described before in relation to other types of cancers, but not Ewing sarcoma.

"People don't die from a primary tumor," he added. "It's cancer metastasizing and spreading through the body that kills. As we learn what makes tumors metastatic, we can search for treatments that may keep primary tumors from making that change or target this specific change once it already has occurred in metastatic tumors."

Use of Archived Tumor Samples

Only 300 to 400 new Ewing sarcoma cases are diagnosed per year in the United States. "The rarity of Ewing sarcoma poses a problem for cancer research," said Schiffman. "Because there are so few cases, it has been difficult in the past to find enough tissue samples to conduct valid studies of the genetics and biology of this disease."

Unlike other genetic analysis techniques, MIPs give very high quality, -wide, high-resolution DNA analysis for clinical samples that have been preserved in formalin and encased in paraffin wax blocks, a process called FFPE. "FFPE has been the standard technique for preserving pathology samples for decades," said Schiffman. "But until recently, genomics technology has not been available to make use of the huge resource these samples represent."

"We analyzed FFPE samples of primary tumors from Ewing sarcoma patients at Primary Children's Medical Center in Salt Lake City from the past 12 years. This doesn't sound like a large , but for this it reflects 10 percent of all cases diagnosed in a given year, so the quantity is significant," he added.

Provided by University of Utah Health Sciences search and more info website

not rated yet  

Rank not rated yet
Related Stories
Relevant PhysicsForums posts

More news stories

ASCO: combo antibody therapy effective for melanoma

(HealthDay)—Concurrent use of two immune checkpoint antibodies—ipilimumab and nivolumab—may be effective for the treatment of advanced melanoma, according to a proof-of-principal study presented in ...

Cancer created 12 hours ago | popularity not rated yet | comments 0

Risk factors ID'd for poor cutaneous cell CA outcomes

(HealthDay)—The risks of metastasis and death associated with cutaneous squamous cell carcinoma (CSCC) are low, but significant, and risk factors for poor outcome include tumor diameter, invasion beyond ...

Cancer created 12 hours ago | popularity not rated yet | comments 0 | with audio podcast

Physical & emotional impairments common, often untreated in people with cancer

A new review finds cancer survivors suffer a diverse and complex set of impairments, affecting virtually every organ system. Writing in CA: A Cancer Journal for Clinicians, Julie Silver, M.D., associate professor at Harvar ...

Cancer created 17 hours ago | popularity not rated yet | comments 0

Calif. doc with 'cancer cure' gets 14 years prison (Update)

(AP)—A California doctor has been sentenced to 14 years in federal prison for bilking her patients out of more than $1 million by promising that an herbal supplement could cure late-stage cancer and other diseases.

Cancer created 17 hours ago | popularity not rated yet | comments 0

New protein-targeting drug shows promise in early trial for patients with high-risk CLL

A new oral targeted drug, idelalisib (GS-1101), has the potential to stave off the need for additional treatments for relapsed or treatment-resistant chronic lymphocytic leukemia (CLL), according to a study led in part by ...

Cancer created 19 hours ago | popularity not rated yet | comments 0 | with audio podcast


AIDS science at 30: 'Cure' now part of lexicon

Big names in medicine are set to give an upbeat assessment of the war on AIDS on Tuesday, 30 years after French researchers identified the virus that causes the disease.

For combat veterans suffering from post-traumatic stress disorder, 'fear circuitry' in the brain never rests

Chronic trauma can inflict lasting damage to brain regions associated with fear and anxiety. Previous imaging studies of people with post-traumatic stress disorder, or PTSD, have shown that these brain regions can over-or ...

Temporal processing in the olfactory system

The neural machinery underlying our olfactory sense continues to be an enigma for neuroscience. A recent review in Neuron seeks to expand traditional ideas about how neurons in the olfactory bulb might encode information about ...

Melon focus headband turns to Kickstarter for rollout plans

(Medical Xpress)—What if the quality of your work depends more on your focus on the piano keys or canvas or laptop than your musical or painting or computing skills? If target users can be convinced, they ...

Now we know why old scizophrenia medicine works on antibiotics-resistant bacteria

In 2008 researchers from the University of Southern Denmark showed that the drug thioridazine, which has previously been used to treat schizophrenia, is also a powerful weapon against antibiotic-resistant bacteria such as ...

Study identifies new approach to improving treatment for MS and other conditions

(Medical Xpress)—Working with lab mice models of multiple sclerosis (MS), UC Davis scientists have detected a novel molecular target for the design of drugs that could be safer and more effective than current FDA-approved ...